Merck wins second Vioxx trial

Share this article:
The jury in the Atlantic City, N.J. Vioxx trial has found Merck not liable.
Merck lawyers persuaded jurors that the heart attack suffered by Idaho postal worker Frederick Humeston was unrelated to his two-month use of Vioxx, citing a host of other cardiovascular risk factors suffered by the plaintiff.
The verdict, following the $253 million decision against Merck in plaintiff-friendly Angleton, Texas last August, should provide a big boost for morale at Merck and could have implications for future Vioxx litigation, as a string of wins for Merck or a mixed record could deter trial lawyers from pursuing lengthy and costly lawsuits against the company. The firm still faces more than 6,000 suits alleging injuries due to Vioxx, which Merck pulled little more than a year ago after studies showed the drug increased cardiovascular risks in patients with preexisting heart conditions.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...